Kamitori Shigehiro, Ohtaki Akashi, Ino Hironori, Takeuchi Michio
Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo 184-8588, Japan.
J Mol Biol. 2003 Mar 7;326(5):1503-11. doi: 10.1016/s0022-2836(03)00078-0.
The X-ray structures of Aspergillus oryzae aspartic proteinase (AOAP) and its complex with inhibitor pepstatin have been determined at 1.9A resolution. AOAP was crystallized in an orthorhombic system with the space group P2(1)2(1)2(1) and cell dimensions of a=49.4A, b=79.4A, and c=93.6A. By the soaking of pepstatin, crystals are transformed into a monoclinic system with the space group C2 and cell dimensions of a=106.8A, b=38.6A, c=78.7A, and beta=120.3 degrees. The structures of AOAP and AOAP/pepstatin complex were refined to an R-factor of 0.177 (R(free)=0.213) and of 0.185 (0.221), respectively. AOAP has a crescent-shaped structure with two lobes (N-lobe and C-lobe) and the deep active site cleft is constructed between them. At the center of the active site cleft, two Asp residues (Asp33 and Asp214) form the active dyad with a hydrogen bonding solvent molecule between them. Pepstatin binds to the active site cleft via hydrogen bonds and hydrophobic interactions with the enzyme. The structures of AOAP and AOAP/pepstatin complex including interactions between the enzyme and pepstatin are very similar to those of other structure-solved aspartic proteinases and their complexes with pepstatin. Generally, aspartic proteinases cleave a peptide bond between hydrophobic amino acid residues, but AOAP can also recognize the Lys/Arg residue as well as hydrophobic amino acid residues, leading to the activation of trypsinogen and chymotrypsinogen. The X-ray structure of AOAP/pepstatin complex and preliminary modeling show two possible sites of recognition for the positively charged groups of Lys/Arg residues around the active site of AOAP.
米曲霉天冬氨酸蛋白酶(AOAP)及其与抑制剂胃蛋白酶抑制剂复合物的X射线结构已在1.9埃分辨率下测定。AOAP在正交晶系中结晶,空间群为P2(1)2(1)2(1),晶胞参数为a = 49.4埃、b = 79.4埃和c = 93.6埃。通过浸泡胃蛋白酶抑制剂,晶体转变为单斜晶系,空间群为C2,晶胞参数为a = 106.8埃、b = 38.6埃、c = 78.7埃,β = 120.3°。AOAP和AOAP/胃蛋白酶抑制剂复合物的结构分别精修至R因子为0.177(R(free)=0.213)和0.185(0.221)。AOAP具有新月形结构,有两个叶(N叶和C叶),它们之间形成了深的活性位点裂隙。在活性位点裂隙的中心,两个天冬氨酸残基(Asp33和Asp214)形成活性二元组,它们之间有一个氢键溶剂分子。胃蛋白酶抑制剂通过氢键和与酶的疏水相互作用与活性位点裂隙结合。AOAP和AOAP/胃蛋白酶抑制剂复合物的结构,包括酶与胃蛋白酶抑制剂之间的相互作用,与其他已解析结构的天冬氨酸蛋白酶及其与胃蛋白酶抑制剂的复合物非常相似。一般来说,天冬氨酸蛋白酶在疏水氨基酸残基之间切割肽键,但AOAP也能识别赖氨酸/精氨酸残基以及疏水氨基酸残基,从而导致胰蛋白酶原和胰凝乳蛋白酶原的激活。AOAP/胃蛋白酶抑制剂复合物的X射线结构和初步建模显示了AOAP活性位点周围赖氨酸/精氨酸残基带正电基团的两个可能识别位点。